Impact of non-steroidal anti-inflammatory drugs on morphine-related adverse effects

	n° event/ N°patients (%)		N°		
	NSIAIDs	Control	comparisons		RR [95% CI]
Resp. depression	21/540 (3.9)	24/371 (6.5)	10	- □+	0.65 [0.39 to 1.11]
Nausea	282/555 (51)	202/379 (53)	9	ф	0.92 [0.82 to 1.04]
Vomiting	118/565 (21)	107/390 (27)	9	:□	0.84 [0.67 to 1.04]
Nausea and vomiting	167/758(22)	181/629 (29)	15		0.72 [0.61 to 0.86]
Urinary retention	46/358 (13)	39/266 (15)	7	- Ċ-	1.00 [0.68 to 1.48]
Pruritus	83/763 (11)	79/606 (13)	10	- □	0.78 [0.59 to 1.04]
Dizziness	49/668 (7.3)	42/519 (8.1)	6	<u></u> -	0.88 [0.60 to 1.28]
Sedation*	92/725 (13)	89/579 (15)	11	- <u></u> -¦	0.69 [0.54 to 0.88]
Bowel dysfunction**	2/398 (0.5)	3/395 (0.8)	3	← □	- 0.66 [0.11 to 3.96]
				0.2 1 RR (95% CI)	5

RR: relative risk. CI: confidence interval. A RR <1 indicates less morphine related adverse effects with active compared with placebo. *Sedation or drowsiness or somnolence. **Ileus or constipation or intestinal obstruction. Meta-analyses were performed when data from at least 3 trials or more than 100 patients could be combined. Individual trial data for each meta-analysis are available on http://www.hcuge.ch/anesthesie/data.htm.